Explore

Trendline Trendline
Immunome Grants Stock Options to New Employees Under Nasdaq Rule

Immunome Grants Stock Options to New Employees Under Nasdaq Rule

Immunome Grants Stock Options to New Employees Under Nasdaq Rule
Trendline Trendline
Puma Biotechnology Grants Inducement Awards to New Employees Under Nasdaq Rule

Puma Biotechnology Grants Inducement Awards to New Employees Under Nasdaq Rule

Puma Biotechnology Grants Inducement Awards to New Employees Under Nasdaq Rule
Trendline Trendline
Parabilis Biotech Targets $476 Million IPO to Advance Cancer Treatment

Parabilis Biotech Targets $476 Million IPO to Advance Cancer Treatment

Parabilis Biotech Targets $476 Million IPO to Advance Cancer Treatment
Trendline Trendline
Parabilis Biotech Plans $476 Million IPO to Advance Cancer Drug Development

Parabilis Biotech Plans $476 Million IPO to Advance Cancer Drug Development

Parabilis Biotech Plans $476 Million IPO to Advance Cancer Drug Development
Trendline Trendline
Onchilles Pharma Begins Phase 1/2 Trial of N17350 for Advanced Solid Tumors

Onchilles Pharma Begins Phase 1/2 Trial of N17350 for Advanced Solid Tumors

Onchilles Pharma Begins Phase 1/2 Trial of N17350 for Advanced Solid Tumors
Trendline Trendline
Regeneron Expands Collaboration with CytomX for Cancer Therapy Development

Regeneron Expands Collaboration with CytomX for Cancer Therapy Development

Regeneron Expands Collaboration with CytomX for Cancer Therapy Development
Trendline Trendline
Almonty Industries Secures $700 Million Through Notes Offering to Bolster Tungsten Operations

Almonty Industries Secures $700 Million Through Notes Offering to Bolster Tungsten Operations

Almonty Industries Secures $700 Million Through Notes Offering to Bolster Tungsten Operations
Trendline Trendline
Parabilis Biotech Aims for $476 Million IPO to Advance Cancer Treatment

Parabilis Biotech Aims for $476 Million IPO to Advance Cancer Treatment

Parabilis Biotech Aims for $476 Million IPO to Advance Cancer Treatment
Trendline Trendline
Corrixr Therapeutics Appoints Hilary M. Malone as CEO to Drive Cancer Treatment Development

Corrixr Therapeutics Appoints Hilary M. Malone as CEO to Drive Cancer Treatment Development

Corrixr Therapeutics Appoints Hilary M. Malone as CEO to Drive Cancer Treatment Development
Trendline Trendline
IDEAYA and Roche Partner to Develop New Pancreatic Cancer Therapy

IDEAYA and Roche Partner to Develop New Pancreatic Cancer Therapy

IDEAYA and Roche Partner to Develop New Pancreatic Cancer Therapy
Trendline Trendline
Terremoto Biosciences Receives FDA Fast Track Designation for Breast Cancer Drug TER-2013

Terremoto Biosciences Receives FDA Fast Track Designation for Breast Cancer Drug TER-2013

Terremoto Biosciences Receives FDA Fast Track Designation for Breast Cancer Drug TER-2013
Trendline Trendline
Kelun-Biotech Unveils Promising First-in-Human Study Results for B7-H3 ADC SKB500 at ASCO 2026

Kelun-Biotech Unveils Promising First-in-Human Study Results for B7-H3 ADC SKB500 at ASCO 2026

Kelun-Biotech Unveils Promising First-in-Human Study Results for B7-H3 ADC SKB500 at ASCO 2026